Mumbai-based Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., has unveiled an $80 million investment plan to expand its Lexington, Kentucky facility in the US.

The site specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products, playing a vital role in Piramal Pharma Solutions integrated antibody-drug conjugate development and manufacturing program, ADCelerate.

The investment, financed by bank loans and internal accruals, aims to enhance the site's existing capacity and capabilities to meet the demands of a rapidly growing market. With this expansion, Piramal Pharma will strengthen its position as an efficient and reliable global partner for biologic manufacturing, leveraging deep scientific expertise and extensive experience managing complex technical projects.

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new laboratory, and state-of-the-art machinery to scale clients' products effectively. Key additions include a new filling line, two commercial-size lyophilisers, a special capping machine, and an external vial washer. Currently, the Lexington site can manufacture 104 product batches per year (utilisation at peak levels). Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches.

The expansion will create over 40 full-time jobs, contributing to the area's economic development and fostering a diverse, vibrant workforce.